Evidence map›Paper›PMID 21553396›Full record

ArticleCurrent protocols in toxicology2011

Aldehyde reduction by cytochrome P450.

Immaculate Amunom, Sanjay Srivastava, Russell A Prough

Open access · greenAbstract read
In one paragraph

Article in Current protocols in toxicology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Immaculate AmunomXenoTech LLC, Lenexa, Kansas, USA.
Sanjay Srivastava
Russell A Prough
University of Louisville · USSekisui XenoTech (United States) · US

Funding

Role of Platelet Activation and Vascular Pathology in Aldehyde ToxicityP01ES011860 · NIEHS · UNIVERSITY OF LOUISVILLE · PI PIERCE, WILLIAM M · 2003 to 2007
$7.0M
Strategic Vision & Impact on Environmental HealthP30ES014443 · NIEHS · UNIVERSITY OF LOUISVILLE · PI PARRISH, RUDOLPH SANDERS · 2007 to 2010
$4.4M
Atherogenic mechanism of lipid peroxidation-derived aldehydesR01HL095593 · NHLBI · UNIVERSITY OF LOUISVILLE · PI SRIVASTAVA, SANJAY · 2010 to 2013
$1.5M
NHLBI NIH HHS HL95593NHLBI NIH HHS R01 HL095593NIEHS NIH HHS 1P01 ES11860NIEHS NIH HHS 5P30ES014443NIEHS NIH HHS P01 ES011860NIEHS NIH HHS P30 ES014443
6 · The paper itself

Abstract

This protocol describes the procedure for measuring the relative rates of metabolism of the α,β-unsaturated aldehydes 9-anthracene aldehyde (9-AA) and 4-hydroxy-trans-2-nonenal (4-HNE). More specifically, these assays measure the aldehyde reduction reactions of cytochrome P450s (CYPs). They can be performed using liver microsomal or other tissue fractions, spherosome preparations of recombinant CYPs, or recombinant CYPs from other sources. The method for reduction of 9-AA (a model α,β-unsaturated aldehyde) by CYPs was adapted from an assay for 9-anthracene oxidation published by Marini et al. (2003). For reduction of the endogenous aldehyde 4-HNE, the substrate was incubated with CYP in the presence of oxygen and NADPH, and the metabolites were separated by HPLC, using an adaptation of the method by Srivastava et al. (2010). For both 9-AA and 4-HNE, the first step involves incubation of the substrate with the CYP in an appropriate medium. This is followed by quantification of metabolites through by spectrofluorometry (9-AA) or HPLC coupled with a radiometric assay (4-HNE). Metabolite identification can be achieved by HPLC GC/MS analysis. Inhibitors of cytochrome P450 can be utilized to show the role of the hemoprotein or other enzymes in these reduction reactions. The reduction of CYPs is not inhibited by either anaerobiosis or inclusion of CO in the gaseous phase of the reaction mixture. These characteristics are similar to those reported for some cytochrome P450-catalyzed azo reduction reactions.

Indexed as

Biological AssayAldehydesAnimalsAnthracenesChromatography, High Pressure LiquidCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemEnzyme InhibitorsFluorometryGas Chromatography-Mass SpectrometryHumansIsoenzymesOxidation-ReductionSubstrate Specificity4-hydroxy-2-nonenal9-anthraldehydeAldehydesAnthracenesCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemEnzyme InhibitorsIsoenzymes

Identifiers

PMID21553396
PMCPMC3110767
OpenAlexW1548196600

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.